BARDA Vaccine Medical Countermeasures for Pandemic Influenza Preparedness & Response
ID: 75A50126R00001_RFI_SSN_NPIVS-2027Type: Sources Sought
Overview

Buyer

HEALTH AND HUMAN SERVICES, DEPARTMENT OFOFFICE OF ASSISTANT SECRETARY FOR PREPAREDNESS AND RESPONSEBARDA - ASPR / DAAPPO / BARDA DCMAWASHINGTON, DC, 20515, USA

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714)

PSC

HEALTH R&D SERVICES; HEALTH CARE SERVICES; APPLIED RESEARCH (AN12)

Set Aside

No Set aside used (NONE)

Original Source

https://sam.gov/workspace/contract/opp/00d139c6a6c949ae8dd069d36de28667/view
Timeline
    Description

    The Department of Health and Human Services, specifically the Office of Assistant Secretary for Preparedness and Response (BARDA), is seeking qualified contractors to support the development of vaccine medical countermeasures for pandemic influenza preparedness and response. The objective of this Sources Sought Notice (SSN) is to refine requirements and establish long-term partnerships with contractors capable of producing vaccines, antigens, and adjuvants necessary for pandemic preparedness and public health emergencies. This initiative is critical for enhancing the U.S. response to influenza viruses with pandemic potential and ensuring rapid regulatory decisions and manufacturing readiness. Interested parties must submit evidence of eligibility, capabilities statements, and requests to participate by email to Laura Saddison at Laura.Saddison@hhs.gov by 3:00 pm EST on December 19, 2025. This SSN/RFI is for information and planning purposes only and does not constitute a solicitation.

    Point(s) of Contact
    Laura Saddison
    Laura.Saddison@hhs.gov
    Files
    No associated files provided.
    Similar Opportunities
    Biomedical Advanced Research and Development Authority (BARDA) Broad Agency Announcement (BAA)
    Buyer not available
    The Department of Health and Human Services, through the Biomedical Advanced Research and Development Authority (BARDA), is soliciting proposals under the Broad Agency Announcement (BAA) BAA-23-100-SOL-00004 for advanced research and development of Medical Countermeasures (MCMs) targeting chemical, biological, radiological, nuclear threats, and emerging infectious diseases, including pandemic influenza. The initiative aims to enhance public health preparedness by fostering partnerships with private organizations, government laboratories, and academic institutions to expedite the development of life-saving MCMs critical for national health security. Proposals will be evaluated based on scientific merit, technological maturity, and regulatory compliance, with an open submission period running until September 25, 2028, at 4:30 PM Eastern Time. Interested parties should direct inquiries to BARDA-BAA@hhs.gov for further information.
    Domestic Capability Building Activity – Onshoring the Manufacturing of Viral Hemorrhagic Fever Vaccine Candidates
    Buyer not available
    The Department of Health and Human Services, specifically the Office of Assistant Secretary for Preparedness and Response (BARDA), is seeking to enhance domestic biopharmaceutical manufacturing capabilities through a contract focused on onshoring the production of viral hemorrhagic fever vaccine candidates. The primary objective is to transfer the manufacturing processes for Vesicular Stomatitis Virus (VSV) Delta G based vaccine candidates from international sites to domestic Contract Development and Manufacturing Organizations (CDMOs) in the United States, thereby strengthening national health security preparedness against threats like the Marburg and Sudan viruses. This initiative is critical as it addresses the current limited domestic capacity for live viral vector manufacturing, ensuring a robust response to infectious disease challenges. Interested parties must be product sponsors or technology owners with BARDA-sponsored monovalent filovirus vaccine candidates and should prepare for a technology transfer demonstration, as the scope does not include procurement of investigational or licensed products.
    Assay Development for Superior Understanding of Response and Efficacy (ASSURE)
    Buyer not available
    The Department of Health and Human Services, through the Office of Assistant Secretary for Preparedness and Response (ASPR BARDA), is soliciting proposals for the ASSURE program, which focuses on the development of innovative assays to evaluate immune responses to infections and vaccinations. The primary objective is to create multiplexed, high-throughput, scalable, and sample-sparing assays that can assess immune status in response to chemical, biological, radiological, and nuclear (CBRN) threats, pandemic influenza, and other emerging infectious diseases. Approximately $8 million is available for four to five awards, with proposals evaluated based on technical approach, relevant experience, and cost reasonableness. Interested parties must submit an abstract by December 18, 2025, and can contact Rebecca Harmon at rebecca.harmon@ati.org or 843.760.3358 for further information.
    BARDA DRIVe EZ-BAA (EZBAA - 22-100-SOL-00003)
    Buyer not available
    The Department of Health and Human Services, through the Biomedical Advanced Research and Development Authority (BARDA), is soliciting proposals under the Easy Broad Agency Announcement (EZ-BAA) BAA-22-100-SOL-00003, which focuses on innovative research to enhance public health preparedness against various biomedical threats. The initiative encompasses multiple Areas of Interest (AOIs), including the development of medical countermeasures for emerging infectious diseases, repurposing existing drugs for chemical threats, and advancing technologies for at-home diagnostics. Interested parties must have active registration with SAM.gov and are encouraged to engage in pre-submission consultations; abstract submissions are due by specified deadlines, with funding amounts contingent on the quality of proposals and alignment with program goals. For further inquiries, interested vendors can contact the BARDA DCMA DRIVe Team at DRIVeAcquisitions@hhs.gov.
    COVID 19 Tests
    Buyer not available
    The Department of Health and Human Services, specifically the Office of Assistant Secretary for Preparedness and Response, is seeking procurement for COVID-19 tests. The opportunity involves the acquisition of in vitro diagnostic substances, reagents, test kits, and sets, with a focus on ensuring compliance with the Trade Agreements Act (TAA). This procurement is critical for enhancing the nation's testing capabilities in response to the ongoing pandemic. Interested vendors can reach out to Junli Collins at junli.collins@hhs.gov or Judy Williams at judy.williams2@hhs.gov for further details, as outlined in the attached justification document.
    National Immunization Survey - Flu Q2-Q4 2023 Bridge Contract
    Buyer not available
    The Department of Health and Human Services, specifically the Centers for Disease Control and Prevention (CDC), is seeking to continue the National Immunization Survey through a bridge contract for the second to fourth quarters of 2023. This contract, awarded to the National Opinion Research Center (NORC), aims to ensure the timely collection and analysis of immunization data, which is critical for public health decision-making and policy formulation. The justification for this contract was made under the authority of FAR 6.302-2 due to unusual and compelling urgency, and the associated Justification and Approval for Other Than Full and Open Competition (JOFOC) will be available for review for 30 days following the contract award. For further inquiries, interested parties may contact Joshua Houston at pkf5@cdc.gov.
    Scalable Solutions Office (SSO) Mission Office Innovative Solutions Opening (ISO)
    Buyer not available
    The Department of Health and Human Services, through the Advanced Research Projects Agency for Health (ARPA-H), is soliciting proposals for the Innovative Solutions Opening (ISO) under the Scalable Solutions Office (SSO). This initiative aims to develop innovative solutions that enhance healthcare access, affordability, and distribution, particularly in underserved communities, while addressing challenges in biomanufacturing and health technology distribution. The solicitation is open until March 5, 2029, and encourages submissions from academia, non-profits, and for-profit entities, with multiple awards anticipated as Other Transactions. Interested parties must submit a Solution Summary for initial feedback before proceeding with a full proposal, adhering to strict guidelines on intellectual property, research security, and cost proposal requirements. For further details, proposers can reach out through the designated submission portals and must ensure compliance with the updated administrative and national policy requirements outlined in the solicitation documents.
    J&A Procurement of Smallpox (Mpox) Vaccine for the Strategic National Stockpile
    Buyer not available
    The Department of Health and Human Services, specifically the Office of Assistant Secretary for Preparedness and Response (BARDA), is seeking to procure additional doses of the JYNNEOS™ vaccine for the Strategic National Stockpile in response to the ongoing monkeypox outbreak. The procurement aims to rapidly secure 11 million doses of the vaccine by utilizing existing bulk drug substance and to enhance manufacturing capacity through technology transfer to contract manufacturing organizations. The JYNNEOS™ vaccine is critical as it is the only licensed vaccine for both smallpox and monkeypox, making it essential for public health preparedness. Interested parties can contact Yifan Yang at yifan.yang@hhs.gov, with the total estimated value of the contract modification being $992,400,000.
    Online Database of Preventive and Travel Health Information-Enterprise and Aerial Route Intelligence Subscription Services-Request for Information
    Buyer not available
    The Department of Homeland Security (DHS), Office of Health Security (OHS), is seeking qualified vendors to provide an enterprise-level online database and alert service for preventive and travel health information, as part of a Request for Information (RFI). The objective is to enhance DHS workforce health readiness and epidemiological monitoring through a subscription service that includes features such as aerial route risk mapping, continuous updates on infectious diseases, vaccination requirements, and access to medical facilities. This service is critical for ensuring timely, evidence-based information for risk assessment and travel planning for up to 1,000 users, thereby supporting the health and safety of DHS personnel. Interested parties must submit their capability statements by December 10, 2025, and can contact Mark Namoco at mark.namoco@hq.dhs.gov or Brendan Benisek at Brendan.Benisek@hq.dhs.gov for further information.
    National Clinical Vaccination (NCV) Contract Extension
    Buyer not available
    The Department of Homeland Security, specifically the Federal Emergency Management Agency (FEMA), is extending the National Clinical Vaccination (NCV) Contract to secure contractor-managed licensed medical professionals for COVID-19 vaccine administration. This extension aims to support federal assistance to state, local, tribal, and territorial partners in response to Major Disaster Declarations related to the COVID-19 pandemic, in accordance with various legislative acts including the Robert T. Stafford Act and the Public Health Service Act. The services are critical for ensuring effective vaccine distribution and administration during ongoing public health emergencies. Interested parties can reach out to Michael Bonds at michael.bonds@fema.dhs.gov or call 202-257-8893 for further details regarding this opportunity.